NDA 016366 · Otsuka Icu Medcl
Sodium Chloride 0.9% In Plastic Container
Sodium Chloride · Injection
Last checked: Nov 19, 2026Latest source record: Sep 21, 2017 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1972
Feb 24, 1972
Approved uses
1
Original approval plus efficacy supplements
Registered trials
9,299
2,122 Phase 3, 968 recruiting
FAERS reports
75,824
60,821 serious, 6,415 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 2, 2025.
INDICATIONS AND USAGE Intravenous solutions containing sodium chloride are indicated for parenteral replenishment of fluid and sodium chloride as required by the clinical condition of the patient.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Feb 24, 1972 Original approval · Type 5 - New Formulation or New Manufacturer
1 products under this application
- SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER · SODIUM CHLORIDE 900MG/100ML · INJECTABLE, INJECTION · Prescription · TE AP
Clinical trials
Interventional ClinicalTrials.gov studies with "Chloride" as an intervention, any sponsor and status, largest first.
- Introduction of Cholera Vaccine in BangladeshPivotal-lookingCompleted
International Centre for Diarrhoeal Disease Research, BangladeshAcademic, hospital or other
NCT01339845 · 240,000 participants · Start Sep 2009 · Primary completion Dec 2016
Drug: ShanChol · For: Cholera
Sites: Dhaka, Bangladesh
- Vellore Typhoid Vaccine Impact TrialPivotal-lookingCompleted
Christian Medical College, Vellore, IndiaAcademic, hospital or other
NCT05500482 · 72,400 participants · Start May 1, 2023 · Primary completion Jan 31, 2026
Drug: Typhoid conjugate Vaccine · For: Typhoid Fever
Sites: Vellore, India
- Randomised Evaluation of COVID-19 TherapyPivotal-lookingRecruiting
University of OxfordAcademic, hospital or other
NCT04381936 · 70,000 participants (planned) · Start Mar 19, 2020 · Primary completion Sep 30, 2028
Drug: Lopinavir-Ritonavir; Corticosteroid and 20 more · For: Pneumonia
Sites: Brussels, Belgium; Tallinn, Estonia; Paris, France · 16 sites in all
- Protective Effect, Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Anhui ProvinceStatus unknown
Sinovac (Dalian) Vaccine Technology Co., Ltd.Industry
NCT05470855 · 45,400 participants (planned) · Start Jul 6, 2022 · Primary completion Nov 30, 2022
Drug: Live attenuated varicella vaccine · For: Varicella
Sites: Anqing, China; Chuzhou, China; Fuyang, China · 5 sites in all
- Crystalloid FLUID Choices for Resuscitation of Hospitalized PatientsPivotal-lookingCompleted
Ottawa Hospital Research InstituteAcademic, hospital or other
NCT04512950 · 43,626 participants · Start Aug 15, 2016 · Primary completion Jun 13, 2020
Drug: Ringer's lactate; 0.9% saline · For: Fluid Therapy
Sites: Hamilton, Canada; London, Canada; Ottawa, Canada · 7 sites in all
- Tranexamic Acid to Prevent Heavy Bleeding After Childbirth in Women at Higher RiskPivotal-lookingRecruiting
London School of Hygiene and Tropical MedicineAcademic, hospital or other
NCT05562609 · 40,000 participants (planned) · Start Apr 22, 2024 · Primary completion Sep 2027
Drug: Tranexamic acid · For: Postpartum Hemorrhage
Sites: Mbeya, Tanzania
- A Global Phase III Clinical Trial of Recombinant COVID- 19 Vaccine (Sf9 Cells)Pivotal-lookingCompleted
WestVac Biopharma Co., Ltd.Industry
NCT04904471 · 39,663 participants · Start Jun 15, 2021 · Primary completion Jan 31, 2022
Drug: Recombinant COVID-19 vaccine (Sf9 cells) · For: COVID-19
Sites: Bekasi, Indonesia; Malang, Indonesia; Surabaya, Indonesia · 24 sites in all
Sinovac (Dalian) Vaccine Technology Co., Ltd.Industry
NCT05460429 · 37,920 participants (planned) · Start Jul 30, 2022 · Primary completion Mar 15, 2023
Drug: Live attenuated varicella vaccine · For: Varicella
Sites: Chuzhou, China; Lishui, China; Quzhou, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- myelosuppression5,526
- nausea5,445
- dyspnoea4,775
- off label use4,708
- headache4,416
- pyrexia4,328
- fatigue4,226
- vomiting3,888
- diarrhoea3,774
- pneumonia3,446
- pain2,969
- white blood cell count decreased2,947
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 118 |
| 2005 | 182 |
| 2006 | 272 |
| 2007 | 248 |
| 2008 | 266 |
| 2009 | 413 |
| 2010 | 399 |
| 2011 | 585 |
| 2012 | 852 |
| 2013 | 690 |
| 2014 | 1,147 |
| 2015 | 2,148 |
| 2016 | 3,096 |
| 2017 | 2,485 |
| 2018 | 3,596 |
| 2019 | 5,072 |
| 2020 | 6,387 |
| 2021 | 5,734 |
| 2022 | 7,390 |
| 2023 | 7,783 |
| 2024 | 9,511 |
| 2025 | 9,912 |
| 2026 | 7,535 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Fluid resuscitation with balanced electrolyte solutions results in faster resolution of diabetic ketoacidosis than with 0.9% saline in adults - A systematic review and meta-analysis.
Szabó GV, Szigetváry C, Turan C, et al. · Diabetes Metab Res Rev 2024 · Meta-Analysis, Systematic Review
- Balanced crystalloid solutions versus 0.9% saline for treating acute diarrhoea and severe dehydration in children.
Florez ID, Sierra J, Pérez-Gaxiola G · Cochrane Database Syst Rev 2023 · Meta-Analysis, Systematic Review
- Resuscitation with blood products in patients with trauma-related haemorrhagic shock receiving prehospital care (RePHILL): a multicentre, open-label, randomised, controlled, phase 3 trial.
Crombie N, Doughty HA, Bishop JRB, et al. · Lancet Haematol 2022 · Clinical Trial, Phase III, Multicenter Study
- Efficacy and safety of isotonic versus hypotonic intravenous maintenance fluids in hospitalized children: an updated systematic review and meta-analysis of randomized controlled trials.
Amer BE, Abdelwahab OA, Abdelaziz A, et al. · Pediatr Nephrol 2024 · Meta-Analysis, Systematic Review
- Intravenous Calcium to Decrease Blood Loss During Intrapartum Cesarean Delivery: A Randomized Controlled Trial.
Ansari JR, Yarmosh A, Michel G, et al. · Obstet Gynecol 2024 · Randomized Controlled Trial, Equivalence Trial
- Clinical study of continuous micropump infusion of atropine and pralidoxime chloride for treatment of severe acute organophosphorus insecticide poisoning.
Liu HX, Liu CF, Yang WH · J Chin Med Assoc 2015 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
Sponsor: Otsuka
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.